Integrative Physiology |
From the Department of Physiology, Tulane University School of Medicine, New Orleans, La.
Correspondence to Dewan S.A. Majid, PhD, Department of Physiology SL39, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112.
| Abstract |
|---|
|
|
|---|
Key Words: renal regional blood flow laser-Doppler flowmetry nitrate/nitrite excretion
| Introduction |
|---|
|
|
|---|
Inhibition of nitric oxide (NO) synthesis in rats was shown to decrease RIHP and attenuate RIHP responses to changes in renal perfusion pressure.3 Moreover, selective inhibition of NO in the rat renal medulla13 and the administration of the NO precursor L-arginine to Dahl salt-sensitive rats14 have been shown to influence RIHP. Intrarenal administration of agents that elicit NO release, such as acetylcholine and bradykinin, have also been shown to increase RIHP,2 15 whereas renal vasodilator agents such as secretin that do not involve cGMP as a second messenger16 have failed to elicit changes in RIHP.2 15 These findings suggest that changes in RIHP may be more closely associated with alterations in intrarenal NO activity during changes in RAP rather than with specific changes in regional hemodynamics.11
The present investigation was designed to examine the link between intrarenal NO activity and RIHP during changes in RAP in anesthetized dogs. To assess RIHP, a microtip catheter transducer was placed under the renal capsule.17 This procedure was preferred because it did not require insertion into the cortical tissue and thus minimized disruption of the renal microcirculation.4 RIHP and other renal responses were evaluated before and during inhibition of NO synthase by nitro-L-arginine (NLA) and also during renal arterial infusion of NO donors. The objective was to evaluate RIHP responses to changes in RAP during control conditions, after blockade of endogenous NO formation, and after infusion of NO donors, which would restore a relatively constant level of intrarenal NO activity but would not lead to changes in intrarenal NO in response to changes in arterial pressure.18
| Materials and Methods |
|---|
|
|
|---|
Measurement of RIHP
A microtip catheter transducer (Millar Instruments,
Inc) was placed under the renal capsule to measure
RIHP.17 This device consists
of a microtransducer mounted on the tip of an insulated wire
catheter,4 which can be
connected to the recording equipment (model D, Grass Instruments). A
small incision was created in the renal capsule for introduction of the
catheter transducer, and the opening was then sealed by applying agar.
The microtransducer was calibrated electronically (0 to 20 mm Hg
pressure range) with a standard calibration device before and after the
experimental protocol. Reference 0 pressure was taken by placing the
microtransducer at the opening of the renal capsule. This transducer
catheter was found highly responsive to constriction of the renal vein
and occlusion of the ureter and to intrarenal infusion of the
vasodilators acetylcholine and bradykinin. We observed in separate
anesthetized dogs21 that
acetylcholine increased RIHP from 2.7±0.6 to 6.9±1.5 mm Hg
(P<0.01; n=7) and bradykinin
increased RIHP from 2.0±0.4 to 7.9±1.9 mm Hg
(P<0.05; n=4) without
significant changes in RAP.
After completion of surgery, a 2.5% solution of inulin in
normal saline was administered into the jugular vein. An initial dose
of 1.6 mL/kg body weight was followed by a continuous infusion of 0.03
mL · min-1 · kg-1
for at least 45 minutes before the implementation of the experimental
protocol. Basal level of arterial pressure in these dogs was raised to
140 mm Hg by partial occlusion of both common carotid arteries to
allow evaluation of the arterial pressure-RIHP relationship over a
wider range of RAP. Urine samples were collected for 2 consecutive
10-minute periods at the spontaneous RAP of
140 mm Hg. At the
midpoint of each urine collection period, an arterial blood sample (2
mL) was taken to measure plasma inulin, sodium, and potassium
concentrations. After control measurements, step reductions in RAP
(
110 and
80 mm Hg) were produced by adjusting a renal arterial
clamp. At each level of RAP, a period of at least 5 minutes was allowed
for stabilization before a 10-minute urine collection was made. After
the last sample was collected at reduced RAP, the clamp was released to
return to control RAP. To inhibit NO synthesis, a continuous
intra-arterial infusion of NLA (Aldrich Chemical Co) was initiated at a
rate of 50
µg · kg-1 ·
min-1.18 19
After 30 minutes of NLA infusion, the protocol was repeated. After
re-establishment of the control RAP, a continuous infusion of an NO
donor was added to the NLA
infusion.18 NO donors used
were
S-nitroso-n-acetylpenicillamine
(2
µg · kg-1 ·
min-1; n=3,
Sigma) and diethylamine/NO complex (0.3
µg · kg-1
· min-1;
n=3, Sigma). As both of these NO donors showed similar responses, the
values were pooled together and presented as one group. Ten minutes
after the initiation of combined NO donor and NLA infusion, the same
protocol was repeated.
Inulin, sodium, and potassium and osmolar concentrations in
urine and plasma were measured as previously
reported.6 11 12 18 19 20
Urine concentrations of nitrate and nitrite
(NOx) were measured using the Greiss reaction
technique after enzymatic reductions of nitrate to nitrite in the
samples as previously
reported.11 12 19
Values are reported as mean±SEM. Statistical comparisons of
differences in the responses were conducted with ANOVA for repeated
measures followed by the Newman-Keuls test. Correlation of the
responses were made by the Spearman test. Differences in the mean
values were deemed significant at a value of
P
0.05.
| Results |
|---|
|
|
|---|
|
|
|
RIHP and Renal Responses to Reductions in RAP
During Infusions of NLA and NO Donor Agents
Figure 1A
illustrates the RAP-induced changes in RIHP during
NO synthase inhibition as well as during infusion of NO donors. In
response to NLA administration, RIHP decreased significantly (1.9±0.5
mm Hg; P<0.05). As previously
reported, CBF and MBF decreased concomitantly with total RBF during NO
synthase
inhibition.9 12
During NLA treatment, RIHP was not altered significantly in response to
reductions in RAP
(Figure 1A
). After addition of NO donor infusion, RIHP
increased toward control levels (4.3±0.9 mm Hg;
P<0.05 versus NLA period).
Although control values of RIHP were restored after NO donor infusion
to the NLA-treated dogs, RIHP did not respond to reductions in RAP as
had been observed during control conditions, and RIHP exhibited
autoregulation in association with CBF and MBF autoregulation
(Figure 1A
). The slopes of the RAP-versus-RIHP relations were
significantly reduced from 0.041±0.016 to 0.0002±0.003
mm Hg · mm Hg-1(P<0.001)
during the NLA period and to -0.007±0.007
(P<0.05) during the NLA+NO
donor period. The slopes of these relationships during NLA and NLA+NO
donor infusions were not significantly different from 0.
The relationship between RAP and
UNOxV was likewise markedly attenuated during NO
synthase inhibition as well as during infusion of NO donor agents
(Figure 2B
). As reported
previously,11 12 19
NO synthase inhibition by NLA administration resulted in significant
decreases in UNOxV to 0.9±0.1
nmol · min-1 · g-1.
NO donor agent infusion after NLA administration restored the
UNOxV level to 1.5±0.1 nmol ·
min-1 · g-1.
The mean slope of the RAP-versus-UNOxV relation
was significantly reduced from 0.014±0.003 to 0.002±0.001
nmol · min-1 · g-1 · mm Hg-1
(P<0.05) during the NLA period
and to 0.001±0.004
nmol · min-1 · g-1 ·
mm Hg-1
(P<0.05) during NLA+NO donor
infusion. The slopes of the relationship between RAP and
UNOxV during the NLA or NO donor infusion period
were not significantly different from 0. In addition, autoregulatory
efficiency for total or regional blood flows remained intact during all
of these periods
(Figure 2
and the
Table
).
The glomerular filtration rate did not change significantly
during NLA or NO donor infusion and remained autoregulated during
changes in RAP
(Table
).
As reported
previously,11 12 18 19
there were decreases in urine flow, sodium excretion, and fractional
excretion of sodium during NO inhibition that were restored to close to
control values during NO donor infusion
(Table
).
Importantly, the NO donors did not restore the slopes of the
relationship between RAP and sodium excretion or
UNOxV.
| Discussion |
|---|
|
|
|---|
The commonly used techniques to measure RIHP reported previously include polyethylene matrix capsules2 15 or microtransducers4 implanted either acutely or chronically in the renal parenchyma and insertion of a catheter into the subcapsular interstitial space.17 The subcapsular space is considered a part of the renal interstitium and is in close functional connection with the deeper interstitial space, as it has been shown that injection of labeled albumin into the subcapsular space rapidly appeared in the hilar lymph.17 The measurement of RIHP from the subcapsular space was preferred to the implantation procedures in the present study to avoid possible tissue injury and tearing of glomerular and peritubular capillaries. It was reported that pressure in the subcapsular space was in the range of 2 to 7 mm Hg, measured using a micropipette (tip diameter, 1 to 2 µm) connected with a polyethylene catheter filled with paraffin oil.17 The subcapsular pressure recorded in the present study using the microtip transducer connected with insulated wire catheter is within the range that has been reported previously.17
The present data demonstrate that RIHP decreases during NO synthase inhibition and increases back to control levels during NO donor infusion. Studies in rats3 have demonstrated that NO synthase inhibition results in decreases in RIHP and prevents arterial pressuredependent changes in RIHP. Increases in NO production rate elicited by L-arginine infusion in rats also caused a rise in RIHP.14 We have also observed that intrarenal administration of the NO agonists acetylcholine and bradykinin in our dog preparations resulted in increases in RIHP, which were also associated with increases in UNOxV.21 Additionally, it was observed that another renal vasodilator, secretin, which did not cause changes in UNOxV, likewise failed to cause any significant changes in RIHP.21 Collectively, these findings support a causal relationship between RIHP and intrarenal NO activity. However, there are also reports showing increases in RIHP in response to acute systemic administration of NO inhibitors in rats.22 23 24 25 Although the reasons for these contrasting findings are not yet clear, they have uniformly been observed in response to systemic administration of NOS inhibitors. Thus, these contrasting findings may not be specific to intrarenal NO inhibition but could be mediated by other factors such as systemic hypertension and inhibition of renal nerves via changes in baroreceptor activity or release of a secondary factor.22 23 24 25
In our experimental preparation in dogs, we have not observed any role played by MBF in mediating RIHP changes during alterations in RAP, as suggested by some investigators.1 9 10 MBF was seen efficiently autoregulated in dogs even during acutely volume-expanded states.6 Although we have not examined the relationship between NO and RIHP under conditions of acute volume expansion, in the present study the dogs were given a salt load for 3 days before the experiment, which could have caused a mild volume-expanded state. There are reports that volume loading increases both RIHP and NO production in various experimental animal models.1 6 10 13 Thus, it can be speculated that there would be an enhancement of the relationship between NO and RIHP during an increase in body fluid volume.
When intrarenal NO levels were restored by NO donors but
were prevented from changing because the constant-rate infusion of NO
donor was superimposed on the endogenous NO inhibition, the
relationship between RAP and RIHP remained markedly attenuated and was
not restored to that seen in the control conditions
(Figure 1
). These results indicate that alterations in
intrarenal NO activity rather than the simple presence of NO are
requisite for RAP-induced changes in RIHP. RIHP is regulated by a
variety of factors, which determine the net flow of fluid into and out
of the renal interstitium.5
As a consequence of multiple transport mechanisms, the renal tubules
generate transtubular solute concentration gradients, which are
responsible for net fluid reabsorption. The bulk of the fluid
transferred into the renal interstitial compartment is then reabsorbed
by the peritubular capillaries into the vascular compartment to be
removed from the kidney. The rate of fluid uptake is determined by the
filtration coefficient of the peritubular capillaries and the net force
for peritubular capillary uptake, which is dependent on the
transcapillary hydrostatic and colloid osmotic gradients. The
steady-state RIHP that results provides the force needed to balance net
peritubular capillary uptake with net tubular reabsorption rate. The
exact mechanisms of how RIHP may be influenced by the alterations in NO
activity are not yet clearly understood. However, there are several
studies indicating that NO influences microvascular endothelial
permeability.26 27 28 29 30
Although the role of NO in the renal microvascular permeability has not
yet been examined, studies conducted in other vascular beds suggest
that peritubular capillary permeability may be influenced by
alterations in intrarenal NO and thus could influence
RIHP.26 27 29 30
Thus, one possible mechanism by which increased NO could increase RIHP
is by decreasing the filtration
coefficient.27 30
It was reported, however, that hydraulic conductivity in frog
mesenteric capillaries was increased by luminal exposure of a NO donor
agent, sodium nitroprusside, and decreased by superfusion with a NO
inhibitor
agent.31 32 These
findings indicate that NO can elicit changes in RIHP by altering the
filtration coefficient
(Kf) of
the peritubular capillary membrane, but the available data indicate
that such changes are opposite to those required.
Because peritubular capillary pressure is greater than RIHP,
the hydrostatic pressure gradient
(Pc-Pi) is positive,
favoring net fluid efflux. However, this positive hydrostatic pressure
gradient is countered by the net colloid osmotic gradient
(
c-
i), which is
generally greater than the hydrostatic pressure gradient in the
peritubular capillaries and is recognized as being the principal
driving force for fluid reabsorption. However, the interstitial colloid
osmotic pressure (
i) partially offsets that
net reabsorptive force in the peritubular capillary and is due
primarily to protein leakage from the peritubular capillaries into the
renal interstitium. At steady state, the net protein leak-out is
balanced by the net protein return via renal lymphatics. In addition,
the effective colloid osmotic pressure is determined by the reflection
coefficient (
), which determines the actual effectiveness of the
colloid osmotic gradient across the peritubular capillary wall. NO has
been implicated in the control of capillary permeability for
macromolecules,29 which
could influence
and thus could lead to an alteration in RIHP in the
renal interstitium. It has been reported that the osmotic reflection
coefficient for albumin in the pulmonary vessels is decreased by
administration of NO inhibitors at high intravascular pressure during
lung ischemia.33 To the
extent that intrarenal NO is able to influence
, the increases in
intrarenal NO due to increases in RAP could reduce the effective
colloid osmotic pressure. Thus, the efficiency of net peritubular
capillary uptake would be diminished leading to an accumulation of
volume in the renal interstitial compartment. The resultant effect
would be a rise in RIHP sufficient to compensate for the reduced net
colloid osmotic pressure gradients. Thus, the RAP-associated changes in
RIHP could occur in the absence of any other hemodynamic changes and
would be associated primarily with the concomitant changes in
intrarenal NO activity. However, further studies are required to
examine the exact mechanism that is involved in NO-mediated changes in
RIHP.
Although the mechanisms of NO to influence microvascular endothelial permeability are not yet clearly defined, the available evidence indicates that NO-dependent changes in cGMP may be involved in this process.29 It is conceivable that NO-induced permeability changes in renal peritubular capillaries may involve activation of cGMP. In the present study, we have observed that a change in RIHP occurs within a minute of inducing a change in RAP. In our earlier studies using NO electrodes in the renal interstitium,11 12 we have also observed that a change in renal interstitial NO concentration occurred within a minute of alterations in RAP. Thus, considering the kinetics observed in the RIHP responses to changes in RAP, it is reasonable to speculate that the alterations in RIHP are not due directly to the changes in RAP but require a secondary stimulus such as NO-induced permeability changes in renal peritubular capillaries. However, further experiments are needed to clarify the mechanisms involved in these RAP-induced changes in RIHP.
In conclusion, the results of the present investigation indicate that the mechanism mediating arterial pressureinduced changes in RIHP may be due to pressure-dependent alterations in intrarenal NO activity and do not require any associated changes in regional RBF.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2.
Granger JP, Scott
JW. Effects of renal artery pressure on interstitial pressure and Na
excretion during renal vasodilation.
Am J Physiol. 1988;255:F828F833.
3. Nakamura T, Alberola AM, Salazar FJ, Saito Y, Kurashina T, Granger JP, Nagai R. Effects of renal perfusion pressure on renal interstitial hydrostatic pressure and Na+ excretion: role of endothelium-derived nitric oxide. Nephron. 1998;78:104111.[Medline] [Order article via Infotrieve]
4.
Skarlatos S, Brand
PH, Metting PJ, Britton SL. Spontaneous changes in arterial blood
pressure and renal interstitial hydrostatic pressure in conscious rats.
J Physiol (Lond ). 1994;481:743752.
5. Navar LG, Evan AP, Rosivall L. Microcirculation of the kidneys. In: Mortillaro N, ed. The Physiology and Pharmacology of the Microcirculation. New York, NY: Academic Press; 1983:397488.
6.
Majid DSA, Godfrey
M, Navar LG. Pressure natriuresis and renal medullary blood flow in
dogs. Hypertension. 1997;29:10511057.
7. Majid DSA, Navar LG. Nitric oxide in the mediation of pressure natriuresis. Clin Exp Pharmacol Physiol. 1997;24:595599.[Medline] [Order article via Infotrieve]
8. Navar LG, Paul RV, Carmines PK, Chou C-L, Marsh DJ. Intrarenal mechanisms mediating pressure natriuresis: role of angiotensin and prostaglandins. Fed Proc. 1986;45:28852891.[Medline] [Order article via Infotrieve]
9.
Mattson DL, Lu S,
Roman RJ, Cowley AW Jr. Relationship between renal perfusion pressure
and blood flow in different regions of the kidney.
Am J Physiol. 1993;264:R578R583.
10.
Cowley AW Jr,
Mattson DL, Lu S, Roman RJ. The renal medulla and hypertension.
Hypertension. 1995;25:663673.
11.
Majid DSA, Omoro
SA, Chin SY, Navar LG. Intrarenal nitric oxide activity and pressure
natriuresis in anesthetized dogs.
Hypertension. 1998;32:266272.
12.
Majid DSA, Said
KE, Omoro SA. Responses to acute changes in arterial pressure on renal
medullary nitric oxide activity in dogs.
Hypertension. 1999;34:832836.
13.
Mattson DL, Roman
RJ, Cowley AW Jr. Role of nitric oxide in renal papillary blood flow
and sodium excretion.
Hypertension. 1992;19:766769.
14.
Patel AR, Granger
JP, Kirchner KA. L-Arginine
improves transmission of perfusion pressure to the renal interstitium
in Dahl salt-sensitive rats. Am J
Physiol. 1994;266:R1730R1735.
15. Mertz JI, Haas JA, Berndt TJ, Burnett JC Jr, Knox FG. Effects of bradykinin on renal interstitial pressures and proximal tubule reabsorption. Am J Physiol. 1984;247:F82F85.
16. Pearson RK, Anderson B, Dixon JE. Molecular biology of the peptide hormone families. Endocrinol Metab Clin North Am. 1993;22:753774.[Medline] [Order article via Infotrieve]
17. Wunderlich P, Persson E, Schnermann J, Ulfendahl H, Wolgast M. Hydrostatic pressure in the subcapsular interstitial space of rat and dog kidneys. Pflugers Arch. 1971;328:307.[Medline] [Order article via Infotrieve]
18.
Majid DSA,
Williams A, Kadowitz PJ, Navar LG. Renal responses to intra-arterial
administration of nitric oxide donor in dogs.
Hypertension. 1993;22:535541.
19.
Majid DSA,
Godfrey M, Grisham MB, Navar LG. Relation between pressure natriuresis
and urinary excretion of nitrate/nitrite in anesthetized dogs.
Hypertension. 1995;25:860865.
20.
Majid DSA, Navar
LG. Blockade of distal nephron sodium transport attenuates pressure
natriuresis in dogs.
Hypertension. 1994;23:10401045.
21. Majid DSA, Said KE, Omoro SA. Renal interstitial hydrostatic pressure responses to nitric oxide-dependent and independent vasodilators in anesthetized dogs. Hypertension. 1998;32:A617.
22. Baylis C, Harton P, Engels K. Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol. 1990;1:875881.[Abstract]
23.
Gabbai FB,
Thomson SC, Peterson O, Wead L, Malvey K, Blantz RC. Glomerular and
tubular interactions between renal adrenergic activity and nitric
oxide. Am J Physiol. 1995;268:F1004F1008.
24.
Khraibi AA.
Inhibition of nitric oxide causes exaggerated natriuresis in
spontaneously hypertensive rats. Am J
Physiol. 1994;266:F762F766.
25.
Khraibi AA. Role
of renal nerves in natriuresis of L-NMMA infusion in SHR and WKY rats.
Am J Physiol. 1995;269:F17F21.
26.
Baldwin AL,
Thurston G, al Naemi H. Inhibition of nitric oxide synthesis increases
venular permeability and alters endothelial actin cytoskeleton.
Am J Physiol. 1998;274:H1776H1784.
27.
He P, Zeng M,
Curry FE. Effect of nitric oxide synthase inhibitors on basal
microvessel permeability and endothelial cells
[Ca+].
Am J Physiol. 1997;273:H747H755.
28. Kubes P. Nitric oxide and microvascular permeability: a continuing dilemma. Eur Respir J. 1997;10:45.[Medline] [Order article via Infotrieve]
29.
van Hinsbergh
VWM. Endothelial permeability for macromolecules: mechanistic aspects
of pathophysiological modulation.
Arterioscler Thromb Vasc Biol. 1997;17:10181023.
30. Moller AD, Grande P. Role of prostacyclin and nitric oxide in regulation of basal microvascular hydraulic permeability in cat skeletal muscle. J Vasc Res. 1999;36:245252.[Medline] [Order article via Infotrieve]
31.
Meyer DJ Jr,
Huxley VH. Capillary hydraulic conductivity is elevated by
cGMP-dependent vasodilators. Circ
Res. 1992;70:382391.
32.
Rumbaut RE, McKay
MD, Huxley VH. Capillary hydraulic conductivity is decreased by nitric
oxide synthase inhibition. Am J
Physiol. 1995;268:H1856H1861.
33.
Becker PM,
Buchanan W, Sylvester JT. Protective effects of intravascular pressure
and nitric oxide in ischemic lung injury.
J Appl Physiol. 1998;84:803808.
This article has been cited by other articles:
![]() |
A. W. Cowley Jr Renal Medullary Oxidative Stress, Pressure-Natriuresis, and Hypertension Hypertension, November 1, 2008; 52(5): 777 - 786. [Full Text] [PDF] |
||||
![]() |
J. D. Joo, M. Kim, V. D. D'Agati, and H. T. Lee Ischemic Preconditioning Provides Both Acute and Delayed Protection against Renal Ischemia and Reperfusion Injury in Mice J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3115 - 3123. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. K. Dutta, J. Lane, L. J. Roberts II, and D. S. A. Majid Superoxide Formation and Interaction with Nitric Oxide Modulate Systemic Arterial Pressure and Renal Function in Salt-Depleted Dogs Exp Biol Med, March 1, 2006; 231(3): 269 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Dos Santos, A. J. Dahly-Vernon, K. M. Hoagland, and R. J. Roman Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R58 - R68. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Obst, V. Gross, J. Janke, M. Wellner, W. Schneider, and F. C. Luft Pressure Natriuresis in AT2 Receptor-Deficient Mice with L-NAME Hypertension J. Am. Soc. Nephrol., February 1, 2003; 14(2): 303 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Eppel, G. Bergstrom, W. P. Anderson, and R. G. Evans Autoregulation of renal medullary blood flow in rabbits Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R233 - R244. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nishimoto, T. Tomida, H. Matsui, T. Ito, and K. Okumura Decrease in Renal Medullary Endothelial Nitric Oxide Synthase of Fructose-Fed, Salt-Sensitive Hypertensive Rats Hypertension, August 1, 2002; 40(2): 190 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Andersen, N. C. F. Sandgaard, and P. Bie Volume expansion during acute angiotensin II receptor (AT1) blockade and NOS inhibition in conscious dogs Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1140 - R1148. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S.A. Majid and A. Nishiyama Nitric Oxide Blockade Enhances Renal Responses to Superoxide Dismutase Inhibition in Dogs Hypertension, February 1, 2002; 39(2): 293 - 297. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |